

1 **Unusually high risks of COVID-19 mortality with age-related comorbidities: An adjusted**  
2 **method to improve the risk assessment of mortality using the comorbid mortality data.**

3

4 Andrew Antos, Ming Lai Kwong, Timothy Balmorez, Alyssa Villanueva, and

5 Shin Murakami\*.

6

7 Department of Basic Sciences, College of Osteopathic Medicine, Touro University, California,

8 Vallejo, CA.

9

10 \* **Corresponding author:** Shin Murakami, PhD, FGSA, Department of Basic Sciences, College  
11 of Osteopathic Medicine, Touro University California 1310 Club Drive, Mare Island, Vallejo, CA  
12 94592. E-mail: [shin.murakami@tu.edu](mailto:shin.murakami@tu.edu)

13 **Author contributions:** AA, MLK, TB and AV were involved in data analysis and manuscript  
14 preparation. SM has been involved in direction and all aspects of research.

15 **Acknowledgment:** We thank the members of the Murakami laboratory for useful discussion  
16 and technical assistance.

17

## ABSTRACT

18 **Background:** The pandemic of Coronavirus Disease 2019 (COVID-19) has been a threat to  
19 global health. In the US, the Centers for Disease Control and Prevention (CDC) has listed 12  
20 comorbidities within the first tier that increase with the risk of severe illness from COVID-19,  
21 including the comorbidities that are common with increasing age (referred to as age-related  
22 comorbidities) and other comorbidities. However, the current method compares a population  
23 with and without a particular disease (or disorder), which may result in a bias on the results.  
24 Thus, comorbidity risks of COVID-19 mortality may be underestimated.

25 **Objective:** To re-evaluate the mortality data from US States and estimate the odds ratios of  
26 death by major comorbidities with COVID-19, we incorporated the control population with no  
27 comorbidity reported and assessed the risk of COVID-19 mortality with comorbidity.

28 **Methods:** We collected all the comorbidity data from the Public Health websites of fifty US  
29 States and Washington DC originally accessed on December 2020. The timing of the data  
30 collection should allow minimizing a bias from the COVID-19 vaccines and new COVID-19  
31 variants. The comorbidity demographic data were extracted from the State Public Health data  
32 made available online. Using the inverse-variance random-effects model, we performed a  
33 comparative analysis and estimated the odds ratio of deaths by COVID-19 with pre-existing  
34 comorbidities.

35 **Results:** A total of 39,451 COVID-19 deaths were identified from four States that had  
36 comorbidity data, including Alabama, Louisiana, Mississippi, New York. 92.8% of the COVID-19  
37 deaths were associated with pre-existing comorbidity. The risk of mortality associated with at  
38 least one comorbidity combined was 1,113 times higher than that with no comorbidity. The  
39 comparative analysis identified nine comorbidities with odds ratios of up to 35 times significantly  
40 higher than no comorbidities. Of them, the top four comorbidities were: hypertension (odds ratio

41 34.73; 95% CI 3.63-331.91;  $p = 0.002$ ), diabetes (odds ratio 20.16; 95% CI 5.55-73.18;  $p <$   
42 0.00001), cardiovascular disease (odds ratio 18.91; 95% CI 2.88-124.38;  $p = 0.002$ ); and  
43 chronic kidney disease (odds ratio 12.34; 95% CI 9.90-15.39;  $p < 0.00001$ ). Interestingly, lung  
44 disease added only a modest increase in risk (odds ratio 6.69; 95% CI 1.06-42.26;  $p <$   
45 0.00001).

46 **Conclusion:** The aforementioned comorbidities show surprisingly high risks of COVID-19  
47 mortality when compared to the population with no comorbidity. Major comorbidities were  
48 enriched with pre-existing comorbidities that are common with increasing age (cardiovascular  
49 disease, diabetes, and hypertension). The COVID-19 deaths were mostly associated with at  
50 least one comorbidity, which may be a source of the bias leading to the underestimation of the  
51 mortality risks previously reported. We note that the method has limitations stemming primarily  
52 from the availability of the data. Taken together, this type of study is useful to approximate the  
53 risks, which most likely provide an updated awareness of age-related comorbidities.

54

## INTRODUCTION

55 COVID-19 is an infectious disease caused by Severe Acute Respiratory Syndrome  
56 Coronavirus-2 (SARS-CoV-2) [1]. It has infected over 82 million people worldwide and over 19  
57 million people in the United States (John Hopkins University Corona Virus Online Map) [2] with  
58 cases increasing daily. As of 12/30/2020, over 1.8 million people have died from COVID-19  
59 globally, and 341,313 deaths are currently attributed to COVID-19 in the US [2].

60 The Centers for Disease Control and Prevention (CDC) has published a list of medical  
61 conditions that increase the risk of severe illness from COVID-19 [3]. These comorbid diseases  
62 have two tiers; the first tier has 12 conditions that “are (an) increased risk of severe illness from  
63 the virus that causes COVID-19”; and the second tier has 11 conditions that “might be at an  
64 increased risk for severe illness from the virus that causes COVID-19” [4]. The CDC listed 125  
65 publications for the evidence [4] (updated 11/30/2020; Accessed 3/28/2021). Our rationales are  
66 the followings. Firstly, the vast majority of them use data from other countries or mixtures of  
67 different countries. The US has a diverse population and COVID-19 has been disproportionately  
68 impacted compared to the rest of the world; therefore, the risk of COVID-19 should be adjusted  
69 based on the US population. Secondly, the current risk assessment of COVID-19 mortality  
70 compares a population with and without a particular disease (or disorder). If the vast majority of  
71 the COVID-19 deaths are expected to be with comorbidities, the control population without a  
72 particular disease would include the other comorbidities, resulting in a possibility of  
73 underestimation of the mortality risks. We reasoned that the control without pre-existing  
74 comorbidities should be appropriate as a control population for the mortality risk assessment. To  
75 reduce unexpected bias from the incomplete US-State data, we focused on the mortality data as  
76 well as incorporated the format of the systematic review. Our objective is to re-evaluate the  
77 mortality data from US States and estimate the odds ratios of death by major comorbidities with  
78 COVID-19, we incorporated the control population with no comorbidity reported and assessed

79 the risk of COVID-19 mortality with comorbidity. This study provides a new index that provides  
80 an overview of the COVID-19 deaths associated with comorbidity.

## 81 **METHODS**

82 We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses  
83 Protocols (PRISMA) statement [5]. Criteria for eligibility is to have comorbidity data made  
84 available to the public. The US comorbidity data was searched on PubMed and Scopus for  
85 literature search and UpToDate for the clinical overview, using the keywords, “COVID 19 AND  
86 Comorbidity”, “COVID 19 AND Comorbidities AND United States”, “COVID 19 AND  
87 Comorbidities AND United States AND Mortality”, for example. For US-States and CDC data,  
88 fifty State health department, Washington DC websites and the CDC websites were directly  
89 accessed; the links of a total of 52 websites searched are shown in Supplementary Material 1.  
90 All the data were collected from the websites, links and search functions embedded on the  
91 webpages (Originally accessed on June 2020; Updated December 2020). Six states provided  
92 comorbidity data: Alabama, Louisiana, Mississippi, New York, Georgia, and Pennsylvania.  
93 Pennsylvania was not included in our results because the state department reported incomplete  
94 data - noting that 38% of deaths did not include comorbidity data (Pennsylvania Department of  
95 Health) [6]. We found data from a study conducted in the State of Georgia, but this study did not  
96 list the deaths by comorbidity and thus was not included in this study. Data extraction from  
97 reports were made directly from the webpage and duplicated. The webpage links including the  
98 States were listed in the Supplementary Material 2. Confirmation of the data was made  
99 independently by two investigators.

100 The Alabama, Louisiana, Mississippi, and New York state department websites update  
101 the death tolls for their respective states. We referenced the Alabama [7], Mississippi [8], and  
102 New York data [9] which were updated on 12/29/2020. We retrieved Louisiana’s data on  
103 12/17/2020; the Louisiana data were dated on 3/31/2020 [11]. The data surrounding deaths due

104 to COVID-19 in Alabama, Louisiana, Mississippi, and New York were separated and additionally  
105 summed for analysis. Deaths that included comorbidity were separated by their respective state.  
106 Deaths that did not suffer from comorbidity were also separated by state. To estimate the  
107 number of comorbidities in Louisiana, we multiplied the percentages with the total number of  
108 deaths since their data only provided a comorbidity percentage. We were unable to input the  
109 decimal values from the percentage calculations for Louisiana's numerical fields. Thus, we  
110 rounded up if the tenths decimal place was equal to or greater than five and rounded down if the  
111 tenths decimal place was less than five. For New York, we also subtracted the total deaths with  
112 comorbidity from the total deaths from COVID-19 to deduce how many COVID-19 deaths did  
113 not have comorbidity. The risk of bias was independently tested by two investigators. We used  
114 ROBINS-I tool (Risk Of Bias in Non-randomized Studies - of Interventions) [10].

115 To calculate the odds ratios, we used the software, RevMan5 (Cochrane reviews) [12].  
116 The random-effects method was also used to calculate the odds ratios. The inverse variance  
117 method was used since it is a common and simple mode to conduct a meta-analysis. "The  
118 inverse variance method is so named because the weight given to each study is chosen to be  
119 the inverse of the variance of the effect estimate (i.e. one over the square of its standard error).  
120 Thus, larger studies, which have smaller standard errors, are given more weight than smaller  
121 studies, which have larger standard errors. The inverse-variance random-effects model has  
122 been commonly used in the COVID-19 meta-analysis studies, for example, [13] and [14]. This  
123 choice minimizes the imprecision (uncertainty of the pooled effect estimate)." Statistical  
124 heterogeneity is measured as  $I^2 > 0$ . The following interpretations for different heterogeneity  
125 percentages were given: 0% to 40% "might not be important", 30% to 60% "may represent  
126 moderate heterogeneity", 50% to 90% "may represent substantial heterogeneity", and 75% to  
127 100% "is considerable heterogeneity." The "thresholds for the interpretation of  $I^2$  can be  
128 misleading, since the importance of inconsistency depends on several factors." These observed

129 factors include the “magnitude and direction of effects” and “the strength of evidence for  
130 heterogeneity (e.g., P-value from the Chi-squared test, or a confidence interval for  $I^2$ ).”

131 We organized the ten comorbidities between the states to standardize them for analysis  
132 as follows. Hypertension was documented in Mississippi and New York that were included to  
133 estimate odds ratios of hypertension. For cardiovascular disease (CVD), New York listed  
134 detailed diseases with CVD pathologies (atrial fibrillation, coronary artery disease, and stroke  
135 comorbidity) [9] and thus were included under the term CVD. Three states showed the data for  
136 the immunocompromised conditions, liver disease, and neurological disease odds ratios; and  
137 two states for the chronic kidney disease and obesity odds ratio figures. For chronic kidney  
138 diseases (CKD) and renal disease (RD), CKD is a part of Renal Disease (RD), and thus RD  
139 data include CKD; nonetheless, we did perform the analysis of CKD. The WHO designates  
140 stroke as a neurological disorder [15] and the CDC designates it as cardiovascular or  
141 cerebrovascular disease [3]. We followed the CDC designation and thus included stroke data  
142 into the cardiovascular disease odds ratios. New York had more detailed designations than  
143 other States and we treated the New York data as follows. Dementia data were included into  
144 Neurologic Disease, and COPD was included in Lung Disease. In this study, Neurological  
145 disease was called Neurologic disease for the consistency of disease designations. Despite the  
146 designations by the CDC, the four states also did not distinguish the diabetes types (type 1, type  
147 2, other types of diabetes) and is shown as diabetes.

## 148 RESULTS

149 We modified the assessment procedure of the COVID-19 mortality data and used the  
150 control population with no comorbidity (Methods). We focused on mortality data, since the  
151 outcomes from the COVID-19 test results could be influenced by different testing systems and  
152 by how they were administered and recorded. For the reason, we excluded the COVID-19 test  
153 results. Similarly, we excluded hospitalization that may contribute to a bias of the risk

154 assessment. The US comorbidity data was searched on the PubMed and Scopus websites. The  
155 results from queries resulted in a total of 1,484 publications, narrowed down to 169 that included  
156 a total of 10 observational studies and case reports. The studies/reports were reviewed and  
157 data regarding deaths from patients with and without comorbidity in the US were not found  
158 (Accessed June 2020). Thus, the CDC and State websites were directly accessed for  
159 provisional comorbidity data; the links were listed in Supplementary Material 1. The PRISMA  
160 flow diagram on June 2020 is shown in Figure 1. The websites examined were a total of 52. The  
161 CDC had a provisional dataset of “comorbidities and other conditions”; the dataset was  
162 dominated by “pneumonia and influenza”, “respiratory failure” and “hypertensive diseases” [16]  
163 which were mixed with COVID-19 symptoms, causes of deaths and pre-existing conditions.  
164 Thus, we did not use the CDC dataset.

165 We collected all the data available which was originally accessed on June 2020 and  
166 updated on December 2020 by searching the Public Health websites of fifty States and  
167 Washington DC in the US. We have compiled and organized the ten comorbidities between the  
168 states to standardize them for analysis (Table 1). The demography is summarized in  
169 Supplementary Material 2. The risk of bias within studies was low to modest (Figure 5). More  
170 details are described in the Section of Method. A total of 39,451 COVID-19 deaths were found  
171 from four states including Alabama, Louisiana, Mississippi, and New York. The results of the  
172 total deaths and other separations by the state are summarized in Figure 2. Each of the pre-  
173 existing comorbidities associated with COVID-19 is summarized in Figure 3. New York  
174 accounts for most of the total COVID-19 deaths in this study, which may create a bias by  
175 dominating the result. To minimize the bias, we used the random-effects models to control the  
176 results of the odds ratio. As a comparison, New York accounted for 75.4% of the total deaths in  
177 the study while Mississippi accounted for 11.9%. Alabama accounted for 12%, while Louisiana  
178 accounted for 0.6% of the total deaths in the study. Therefore, the random-effects model helped



179 mitigate some of the bias from New York. 92.8% of the COVID-19 mortality was seen in patients  
180 with at least one comorbidity.

181 Table 1 and Figure 3 summarize the results. Nine out of ten comorbidities combined to  
182 show a surprisingly high risk of death due to covid-19, 1,113 times higher (odds ratio, 1113.59;  
183 95% CI, 157.59, 7888.28;  $p < .00001$ ). Of all the comorbidities, the top comorbidities were:  
184 cardiovascular disease; chronic kidney disease, diabetes; and hypertension. Nine comorbidities,  
185 except chronic kidney disease, showed a significant amount of heterogeneity ( $I^2$  value ranging  
186 from 77% to 100%) present which was supported by a strong heterogeneity p-value (ranging  
187 from 0.00001 to 0.01) and high variability in the confidence interval (Table 1). The risk of bias  
188 across studies were low to modest (Figure 5).

189 As shown in Figure 4A, cardiovascular disease has a high risk of death due to covid-19  
190 (odds ratio 18.91; 95% CI 2.88-124.38;  $p = 0.002$ ). Hypertension is often coupled with  
191 cardiovascular disease, and when we combined both hypertension and cardiovascular disease,  
192 the risk was doubled (odds ratio, 40.70; 95% CI 27.06, 61.21;  $p < 0.00001$ ). Figure 4B shows  
193 the chronic kidney disease (CKD) comorbidity data (odds ratio 12.34; 95% CI 9.90-15.39;  $p <$   
194  $0.00001$ ). Importantly, no heterogeneity ( $I^2 = 0\%$ ) was present in CKD which is supported by the  
195 weak P-value ( $P = 0.58$ ) and significant overlap of confidence intervals between the two  
196 studies. Figure 4C shows the diabetes comorbidity data (odds ratio 20.16; 95% CI 5.55-73.18;  $p$   
197  $< 0.00001$ ). Figure 4D shows the hypertension analysis containing comorbidity data (odds ratio  
198 34.73; 95% CI 3.63-331.91;  $p = 0.002$ ).

199 Figure 4E shows the immunocompromised condition comorbidity data (odds ratio, 6.89;  
200 95% CI 3.89, 12.20;  $p < 0.00001$ ); Figure 4F shows the liver disease comorbidity data (odds  
201 ratio, 2.04; 95% CI 3.89, 12.20;  $p = 0.02$ ); and Figure 4G shows the lung disease comorbidity  
202 data (odds ratio, 6.69; 95% CI 1.06, 42.26;  $p = 0.04$ ). The effect of lung disease as a type of  
203 comorbidity may have an overlapping, modest effect of death. Neurological condition (Figure

204 4H) was not significantly different from no comorbidity (odds ratio, 5.41; 95% CI 0.55, 38.63; p =  
205 0.07). It is worth noting that in New York, dementia is one of the leading comorbidities of the  
206 COVID-19 deaths, which will require a more specific detailed analysis. Obesity (Figure 4I) had  
207 an estimate of 9 (95% CI 1.59, 51.06; p = 0.01). The renal disease (Figure 4J) had an estimate  
208 of 7.74 (p = 0.02). A significant amount of heterogeneity ( $I^2 > 77\%$ ;  $P < 0.01$ ) was present in this  
209 analysis, except for chronic kidney disease ( $I^2=0\%$ , heterogeneity P-value = 0.58).

## 210 **DISCUSSION**

211 Age-related health conditions including cardiovascular disease, hypertension, and type 2  
212 diabetes are common in the aging population and have been implicated in late-life diseases  
213 such as Alzheimer's disease [17-18]. The centers for disease control and prevention (CDC)  
214 have listed comorbidities with the risk of severe illness from COVID-19, including the  
215 comorbidities that are common with increasing age (age-related comorbidities) (e.g., heart  
216 conditions, hypertension, and type 2 diabetes) and other comorbidities (e.g., smoking, lung  
217 disease, and genetic conditions such as down syndrome and sickle cell disease). Most of the  
218 previous studies on comorbidities were based on data from other countries. Using the data  
219 available from the US, we estimated the odds ratios of comorbidities within the US population to  
220 assess their impact on mortality from COVID-19. We found age-related comorbidities to be the  
221 major conditions: cardiovascular disease, chronic kidney disease, diabetes, and hypertension.  
222 When cardiovascular disease and hypertension were combined, the odds ratio of mortality  
223 became 40 times higher than without comorbidity. The risks of mortality from COVID-19 in  
224 patients with medical comorbidities appears to be much higher than previous studies that used  
225 non-US data. For example, the CDC refers to the studies about hypertension consist most if not  
226 all of non-US data (cdc.gov accessed on March 2021). The odds ratios were much higher in the  
227 US (odds ratio 34.7; this study) compared to those in studies conducted in non-US-countries  
228 (odds ratios 2.3-6.5 in non-US countries) [e.g., 17-20], which implies that there seems to be a

229 variation among countries. Thus, a more comprehensive study remains to be done with data  
230 from more US states once they become available.

231 We organized the comorbidity categories with consideration given to the varied  
232 definitions of categories between organizations and state reports. In the study, we followed the  
233 CDC categories whenever possible. Adjustments of the categories for the purposes of analysis  
234 in this study are described in the Result and Method sections. We also noted that the CDC has  
235 a detailed list of diseases contributing to the cause of death, which is dominated by “pneumonia  
236 and influenza” and “respiratory failure” in the category [16]. In our analysis, we used pre-existing  
237 comorbidities present in the population of the study. We tried to avoid skewed results by using  
238 the inverse variance method of data analysis to ensure that the data from New York did not  
239 overpower data from the other states. Despite the adjustments, the odds ratios were surprisingly  
240 higher than those estimated based on previous research.

241 Most of the comorbidities showed significantly higher mortality as measured by the odds  
242 ratio. Comorbidities that significantly increase the risk of a severe COVID-19 include  
243 cardiovascular disease, chronic kidney disease, diabetes, hypertension, immunocompromised  
244 condition, liver disease, lung disease, obesity, and renal disease. We could not find a significant  
245 increase in risk due to neurological conditions. Heterogeneity was significantly high for nine  
246 comorbidities, except for chronic kidney disease. Interestingly, dementia, a part of the  
247 neurological conditions, was placed in fourth for comorbidities in New York, while other states  
248 did not have this category. Therefore, it remains contested whether or not dementia shows a  
249 significant increase in mortality with COVID-19.

250 We used an adjusted method that has strengths as follows. Firstly, it uses the control  
251 population with no comorbidities which avoid bias from the population. The control is particularly  
252 important when most of the COVID-19 deaths are associated with one or more comorbidities.  
253 Secondly, the mortality data with comorbidities are readily available to the public, which are

254 expected to be less biased. The sample sizes are similar to the previous systematic review and  
255 meta-analysis studies [4,19-22]. Thirdly, it is relatively simple to perform the assessment  
256 independent of other factors that are expected to have high variability. Finally, we designed the  
257 method that avoids the sources of data ambiguity, such as COVID-19 detection systems and  
258 variation of the severity of COVID-19. In contrast, the method has limitations stemming primarily  
259 from the availability of the data. It is limited to the resources that have comorbidity data made  
260 available to the public, though the limitation is similar to that of the meta-analysis. We were also  
261 not able to identify the data about more than one comorbidity, which cannot be assessed in the  
262 method. Other limitations have been described above (Methods; Results). Since the method  
263 focuses on the mortality data, the outcomes from the results gives an overview of the COVID-19  
264 deaths with and without comorbidity. We also note that the comorbidity criteria are inconsistently  
265 presented among the States. We propose to have a more unified process of presenting the  
266 comorbidities in Public Health data for collaboration purposes.

## 267 **CONCLUSIONS**

268 This study is among one of the first US-based studies to show the risk of mortality from  
269 COVID-19 in patients who suffer from common comorbidities. We successfully compiled the US  
270 COVID-19 mortality data and estimated the risk of death from COVID-19 with and without  
271 comorbidity. This type of study is needed to approximate mortality risk in the context of COVID-  
272 19 so that we can better stratify how to address and manage patients with these comorbidities  
273 from a public health perspective. Nine out of ten comorbidities analyzed were shown to increase  
274 the likelihood of death from COVID-19. We found that in the US population, the odds ratio for  
275 each of these comorbid conditions was higher than that previously seen in the studies  
276 predominantly from outside of the US. We call for a standardized format and distribution of data  
277 be provided by each State regarding COVID-19 morbidity and mortality so that a thorough and  
278 cohesive analysis of data can occur. We also propose to include a control population with no

279 comorbidity when possible to minimize a bias from other health conditions. Altogether, this study  
280 gives an awareness about the comorbidities that are more deleterious than previously  
281 recognized and provides a call to action for the public health community.

282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306

## REFERENCES

1. Fang, L., Karakiulakis, G., & Roth, M. (2020). Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *The Lancet Respiratory Medicine*, 8(4). doi: 10.1016/s2213-2600(20)30116-8  
[https://www.thelancet.com/journals/lanres/article/PIIS2213-2600\(20\)30116-8/fulltext](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30116-8/fulltext)
2. Dong E, Du H, Gardner L. (2020) An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis.* 20(5):533-534. doi: 10.1016/S1473-3099(20)30120-1.  
[https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(20\)30120-1/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30120-1/fulltext)
3. The centers for disease control and prevention (CDC). People with Certain Medical Conditions. COVID-19. Retrieved 18 Aug. 2020 from  
<https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html>
4. The centers for disease control and prevention (CDC). Underlying Medical Conditions Associated with High Risk for Severe COVID-19: Information for Healthcare Providers Retrieved December 29, 2020 from <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html>
5. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med* 6(7): e1000097. doi:10.1371/journal.pmed1000097  
<https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000097>
6. Pennsylvania Department of Health. Weekly Report For Deaths Attributed To COVID-19. Retrieved May 17, 2020 from  
[https://www.health.pa.gov/topics/Documents/Diseases%20and%20Conditions/COVID-19%20Death%20Reports/Weekly%20Report%20of%20Deaths%20Attributed%20to%20COVID-19%20--%202020-05-17.pdf?mod=article\\_inline](https://www.health.pa.gov/topics/Documents/Diseases%20and%20Conditions/COVID-19%20Death%20Reports/Weekly%20Report%20of%20Deaths%20Attributed%20to%20COVID-19%20--%202020-05-17.pdf?mod=article_inline)

- 307 7. Alabama Public Health. Data and Surveillance. Retrieved December 29, 2020 from  
308 <https://www.alabamapublichealth.gov/covid19/data.html>
- 309 8. Mississippi State Department of Health. Interactive Charts: COVID-19 Epidemiological  
310 Charts and Trends. Retrieved December 29, 2020 from  
311 [https://msdh.ms.gov/msdhsite/\\_static/14,21995,420,873.html](https://msdh.ms.gov/msdhsite/_static/14,21995,420,873.html)
- 312 9. New York State Department of Health. Workbook: NYS-COVID19-Tracker. (n.d.).  
313 Retrieved December 30, 2020 from  
314 [https://covid19tracker.health.ny.gov/views/NYS-COVID19-Tracker/NYSDOHCOVID-](https://covid19tracker.health.ny.gov/views/NYS-COVID19-Tracker/NYSDOHCOVID-19Tracker-Fatalities?%3Aembed=yes&%3Atoolbar=no&%3Atabs=n)  
315 [19Tracker-Fatalities?%3Aembed=yes&%3Atoolbar=no&%3Atabs=n](https://covid19tracker.health.ny.gov/views/NYS-COVID19-Tracker/NYSDOHCOVID-19Tracker-Fatalities?%3Aembed=yes&%3Atoolbar=no&%3Atabs=n)
- 316 10. Louisiana Department of Health. Updates for 3/31/2020. (n.d.). Retrieved December 17,  
317 2020 from <https://ldh.la.gov/index.cfm/newsroom/detail/5522>
- 318 11. Sterne JAC, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry  
319 D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ,  
320 Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D,  
321 Rothstein HR, Sandhu L, Santaguida PL, Schünemann HJ, Shea B, Shrier I, Tugwell P,  
322 Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JPT.  
323 ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions.  
324 *BMJ* 2016; 355; i4919; doi: 10.1136/bmj.i4919.  
325 <https://www.bmj.com/content/355/bmj.i4919>
- 326 12. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors).  
327 (2019) *Cochrane Handbook for Systematic Reviews of Interventions*. 2nd Edition.  
328 Chichester (UK): John Wiley & Sons. Cochrane, 2019.  
329 [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).
- 330 13. Miller LE, Bhattacharyya R, Miller AL. (2020) Diabetes mellitus increases the risk of  
331 hospital mortality in patients with Covid-19: Systematic review with meta-analysis.

- 332 Medicine (Baltimore). 2020 Oct 2;99(40):e22439. doi: 10.1097/MD.00000000000022439.  
333 PMID: 33019426 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535849/>
- 334 14. Li J, Yue J, Zhang S, Wu J, Lian R, Zhang R, Cheng P. Medicine (Baltimore). (2020)  
335 Relationship between digestive diseases and COVID-19 severity and mortality: A  
336 protocol for systematic review and meta-analysis. 99(48):e23353. doi:  
337 10.1097/MD.00000000000023353. PMID: 33235103  
338 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710250/>
- 339 15. World Health Organization (WHO). (2016) What are neurological disorders and how  
340 many people are affected by them? (n.d.). Retrieved from [https://www.who.int/news-](https://www.who.int/news-room/q-a-detail/what-are-neurological-disorders)  
341 [room/q-a-detail/what-are-neurological-disorders](https://www.who.int/news-room/q-a-detail/what-are-neurological-disorders)
- 342 16. The centers for disease control and prevention (CDC). Weekly Updates by Select  
343 Demographic and Geographic Characteristics. Retrieved March 31, 2021 from  
344 [https://www.cdc.gov/nchs/nvss/vsrr/covid\\_weekly/index.htm](https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm)
- 345 17. Vahdati Nia B, Kang C, Tran MG, Lee D, Murakami S. (2017) Meta Analysis of Human  
346 AlzGene Database: Benefits and Limitations of Using *C. elegans* for the Study of  
347 Alzheimer's Disease and Co-morbid Conditions. Front Genet. 12;8:55. doi:  
348 10.3389/fgene.2017.00055. <https://doi.org/10.3389/fgene.2017.00055>
- 349 18. Le D, Crouch N, Villanueva A, Ta P, Dmitriyev R, et al. 2020. Evidence-Based Genetics  
350 and Identification of Key Human Alzheimer's Disease Alleles with Co-morbidities. J  
351 Neurol Exp Neurosci 6(1): 20-24. [https://touro scholar.touro.edu/tuocom\\_pubs/139/](https://touro scholar.touro.edu/tuocom_pubs/139/)
- 352 19. Matsushita K, Ding N, Kou M, Hu X, Chen M, Gao Y, Honda Y, Zhao D, Dowdy D, Mok  
353 Y, Ishigami J, Appel LJ. 2020 The Relationship of COVID-19 Severity with  
354 Cardiovascular Disease and Its Traditional Risk Factors: A Systematic Review and  
355 Meta-Analysis. Glob Heart, 15(1):64. doi: 10.5334/gh.814  
356 <https://globalheartjournal.com/article/10.5334/gh.814/>



- 357 20. Guo, X., Y. Zhu, and Y. Hong. 2020 Decreased Mortality of COVID-19 With Renin-  
358 Angiotensin-Aldosterone System Inhibitors Therapy in Patients with Hypertension: A  
359 Meta-Analysis. *Hypertension*, 76(2):e13-e14. doi:  
360 10.1161/HYPERTENSIONAHA.120.15572  
361 <https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.120.15572>
- 362 21. Wu T, Zuo Z, Kang S, Jiang L, Luo X, Xia Z, Liu J, Xiao X, Ye M, Deng M. 2020 Multi-  
363 organ Dysfunction in Patients with COVID-19: A Systematic Review and Meta-analysis.  
364 *Aging Dis*, 11(4): 874-894. doi: 10.14336/AD.2020.0520  
365 <http://www.aginganddisease.org/EN/10.14336/AD.2020.0520>
- 366 22. Zhang J, Wu J, Sun X, Xue H, Shao J, Cai W, Jing Y, Yue M, Dong C. 2020 Association  
367 of hypertension with the severity and fatality of SARS-CoV-2 infection: A meta-analysis.  
368 *Epidemiol Infect* 148:e106. doi: 10.1017/S095026882000117X  
369 [https://www.cambridge.org/core/journals/epidemiology-and-infection/article/association-](https://www.cambridge.org/core/journals/epidemiology-and-infection/article/association-of-hypertension-with-the-severity-and-fatality-of-sarscov2-infection-a-metaanalysis/4116FAD7D866737099F976E7E7FAEB15)  
370 [of-hypertension-with-the-severity-and-fatality-of-sarscov2-infection-a-](https://www.cambridge.org/core/journals/epidemiology-and-infection/article/association-of-hypertension-with-the-severity-and-fatality-of-sarscov2-infection-a-metaanalysis/4116FAD7D866737099F976E7E7FAEB15)  
371 [metaanalysis/4116FAD7D866737099F976E7E7FAEB15](https://www.cambridge.org/core/journals/epidemiology-and-infection/article/association-of-hypertension-with-the-severity-and-fatality-of-sarscov2-infection-a-metaanalysis/4116FAD7D866737099F976E7E7FAEB15)
- 372 **23.** McGuinness, LA, Higgins, JPT. 2020 Risk-of-bias VISualization (robvis): An R package  
373 and Shiny web app for visualizing risk-of-bias assessments. *Res Syn Meth*. 1- 7.  
374 <https://doi.org/10.1002/jrsm.1411>

375

**TABLE**

376 **Table 1. Summary of the odds ratio outcomes.**

| Comorbidity Type              | OR (95% CI)                  | P         | I <sup>2</sup> | Heterogeneity<br>P |
|-------------------------------|------------------------------|-----------|----------------|--------------------|
| Cardiovascular Disease        | 18.91 (2.88, 124.38)         | 0.002     | 100%           | < 0.00001          |
| Chronic Kidney Disease        | 12.34 (9.90, 15.39)          | < 0.00001 | 0%             | 0.58               |
| Diabetes                      | 20.16 (5.55, 73.18)          | < 0.00001 | 99%            | < 0.00001          |
| Hypertension                  | 34.73 (3.63, 331.91)         | 0.002     | 99%            | < 0.00001          |
| Immunocompromised             | 6.89 (3.89, 12.20)           | < 0.00001 | 81%            | 0.006              |
| Liver Disease                 | 2.04 (3.89, 12.20)           | 0.02      | 77%            | 0.01               |
| Lung Disease                  | 6.69 (1.06, 42.26)           | 0.04      | 100%           | < 0.00001          |
| Neurological Disease          | 4.62 (0.55, 38.63)           | 0.16      | 99%            | < 0.00001          |
| Obesity                       | 9.00 (1.59, 51.06)           | 0.01      | 98%            | < 0.00001          |
| Renal Disease                 | 7.74 (1.33, 45.05)           | 0.02      | 100%           | < 0.00001          |
| All comorbidities<br>combined | 1113.59 (157.59,<br>7888.28) | < 0.00001 | 100%           | < 0.00001          |

377

378 Abbreviation: OR (Odds Ratio)

379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401

## FIGURE LEGENDS

**Figure 1.** A flow diagram of this study originally accessed on June 2020. The PRISMA template for researchers was used [5].

**Figure 2.** A total number of COVID-19 deaths first separated by state and then by comorbidity. A list of COVID-19 deaths was identified from a total of 4 US states in 2020, including Alabama, Louisiana, Mississippi, and New York.

**Figure 3.** Summary of the mortality risks by COVID-19 comorbidities.

**Figure 4.** Meta-analysis of the comorbidities with COVID-19. **A.** Cardiovascular disease (CVD). This odds ratio includes atrial fibrillation, coronary artery disease, hypertension, and stroke from New York’s comorbidity data. **B.** Chronic Kidney Disease (CKD). **C.** Diabetes. **D.** Hypertension. **E.** Immunocompromised Condition. **F.** Liver Disease. **G.** Lung Disease. This odds ratio includes Chronic Lung Disease from Alabama’s data and COPD from New York’s data. **H.** Neurological Disease. This odds ratio includes Alzheimer’s disease and Stroke data from New York. **I.** Obesity. **J.** Renal Disease. This odds ratio includes CKD data from Alabama and Louisiana. “Total” columns in the model represent the numerical amount of the total deaths from COVID-19. The “Events” column on the left represents the number of deaths that included the cardiovascular disease comorbidity in that respective state. The “Events” column on the right represents the number of deaths without comorbidity in that respective state.

**Figure 5.** Assessment of the risk of bias using ROBINS-1. Shown are the Traffic light plot (above) and the Summary plot (below). We used comorbidity as an intervention and death as an outcome. No information (Blue) is not applicable to this study. We used a visualization tool as described in [23].




Figure 1




Figure 2






Figure 3


A




B




C




D



E



F



G






Figure 4

H



I



J




Figure 4 cont.






Figure 5

## Supplementary Material 1

The list of the Public Health weblinks of fifty State and the Washington, D.C. websites searched in this study (as of Dec 2020)

1. Alabama: <https://www.alabamapublichealth.gov/index.html>
2. Alaska: <http://hss.state.ak.us/outage.htm>
3. Arizona: <https://www.azdhs.gov/>
4. Arkansas: <https://healthy.arkansas.gov/>
5. California: <https://www.cdph.ca.gov/>
6. Colorado: <https://cdphe.colorado.gov/>
7. Connecticut: <https://portal.ct.gov/dph>
8. Delaware: <https://www.dhss.delaware.gov/dhss/dph/index.html>
9. Washington DC: <https://dchealth.dc.gov/>
10. Florida; <http://www.floridahealth.gov/>
11. Georgia: <https://dph.georgia.gov/>
12. Hawaii: <https://health.hawaii.gov/>
13. Idaho: <https://healthandwelfare.idaho.gov/>
14. Illinois: <https://www.dph.illinois.gov/>
15. Indiana: <https://www.in.gov/isdh/>
16. Iowa: <https://idph.iowa.gov/>
17. Kansas: <https://www.kdheks.gov/>
18. Kentucky: <https://chfs.ky.gov/agencies/dph/Pages/default.aspx>
19. Louisiana: <https://ldh.la.gov/>
20. Maine: <https://www.maine.gov/dhhs/>
21. Maryland: <https://health.maryland.gov/pages/home.aspx>
22. Massachusetts: <https://www.mass.gov/orgs/department-of-public-health>
23. Michigan: <https://www.michigan.gov/mdhhs>
24. Minnesota: <https://www.health.state.mn.us/>
25. Mississippi: <https://msdh.ms.gov/>
26. Missouri: <https://health.mo.gov/index.php>
27. Montana: <https://dphhs.mt.gov/>
28. Nebraska: [dhhs.ne.gov/Pages/default.aspx](https://dhhs.ne.gov/Pages/default.aspx)

29. Nevada: <http://dpbh.nv.gov/>
30. New Hampshire: <https://www.dhhs.nh.gov/>
31. New Jersey: <https://www.nj.gov/health/>
32. New Mexico: <https://www.nmhealth.org/>
33. New York: <https://health.ny.gov/>
34. North Carolina: <https://www.ncdhhs.gov/>
35. North Dakota: <https://www.health.nd.gov/>
36. Ohio: <https://odh.ohio.gov/wps/portal/gov/odh/home>
37. Oklahoma: <https://oklahoma.gov/health.html>
38. Oregon: <https://www.oregon.gov/oha/ph/pages/index.aspx>
39. Pennsylvania: <https://www.health.pa.gov/Pages/default.aspx>
40. Rhode Island: <https://health.ri.gov/>
41. South Carolina: <https://scdhec.gov/>
42. South Dakota: <https://doh.sd.gov/>
43. Tennessee: <https://www.tn.gov/health.html>
44. Texas: <https://dshs.state.tx.us/>
45. Utah: <https://health.utah.gov/>
46. Vermont: <https://www.healthvermont.gov/>
47. Virginia: <https://www.vdh.virginia.gov/>
48. Washington: <https://www.doh.wa.gov/>
49. West Virginia: <https://dhhr.wv.gov/bph/Pages/default.aspx>
50. Wisconsin: <https://www.dhs.wisconsin.gov/>
51. Wyoming: <https://health.wyo.gov/>

## Supplementary Material 2

Demography of the population used in this study.

| State Health Department | # of Deaths | Gender          |                 |              | Race/Ethnics                                  |   |   |                                  |             |   |   | Access Date |
|-------------------------|-------------|-----------------|-----------------|--------------|---|---|---|----------------------------------|-------------|---|---|-------------|
|                         |             | Male            | Female          | Unknown      | White   | Black   | Asian                                       | American Indian or Alaska Native | Unknown     | Other                                       | Hispanic                                      |             |
| Alabama                 | 4,737*      | 2,487<br>(53%)  | 2,240<br>(47%)  | 10<br>(0.2%) | 2,723<br>(58%)                                | 1,544<br>(33%)                                | 18<br>(0.4%)                                | NA                               | 307<br>(7%) | 146<br>(3%)                                 | **  | 12/29/20    |
| Louisiana               | 239         | NA              | NA              | NA           | NA  | NA  | NA  | NA                               | NA          | NA  | NA  | 12/17/20    |
| Mississippi             | 4,719       | NA              | NA              | NA           | 2,441   | 1,964   | 15  | 94                               | 125         | 80  | **  | 12/29/20    |
| New York                | 29,756      | 16,849<br>(57%) | 12,898<br>(43%) | 9<br>(0.0%)  | NYC 27%<br>NYS<br>Excluding<br>NYC 66%<br>*** | NYC 28%<br>NYS<br>Excluding<br>NYC 15%<br>*** | NYC 7%<br>NYS<br>Excluding<br>NYC 4%<br>*** | NA                               | NA          | NYC 4%<br>NYS<br>Excluding<br>NYC 3%<br>*** | NYC 34%<br>NYS<br>Excluding<br>NYC 12%<br>*** | 12/29/20    |

Abbreviations: NA (Not available), NYC (New York City), NYS (New York State).

\* The Alabama percentages by race add up more than 100%. It is a possibility of patients in two or more race.

\*\* Alabama and Mississippi label Hispanic as an ethnicity, but not a race. Alabama reports 109 of the total deaths were of Hispanic ethnicity and Mississippi reports 50 deaths were of Hispanic ethnicity.

\*\*\* NYC data and NYS excluding NYC data were available as percentages shown. The numbers were not available.